BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28416606)

  • 1. TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.
    Liu T; Sun H; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y; Sun B
    Mol Cancer Ther; 2017 Jul; 16(7):1377-1388. PubMed ID: 28416606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
    Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
    Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
    Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
    Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
    Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RSRC2 Expression Inhibits Malignant Progression of Triple-Negative Breast Cancer by Transcriptionally Regulating SCIN Expression.
    Zhao N; Ni C; Fan S; Che N; Li Y; Wang S; Li Y; Dong X; Guo Y; Zhao X; Liu T
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.
    Teslow EA; Mitrea C; Bao B; Mohammad RM; Polin LA; Dyson G; Purrington KS; Bollig-Fischer A
    Mol Oncol; 2019 Apr; 13(4):894-908. PubMed ID: 30636104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
    J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
    Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
    Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.
    Deng L; Liao L; Zhang YL; Yang SY; Hu SY; Andriani L; Ling YX; Ma XY; Zhang FL; Shao ZM; Li DQ
    Sci Adv; 2024 Apr; 10(14):eadj4009. PubMed ID: 38569025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.
    Lin YF; Tseng IJ; Kuo CJ; Lin HY; Chiu IJ; Chiu HW
    J Cell Mol Med; 2018 Apr; 22(4):2458-2468. PubMed ID: 29392887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis.
    Chen F; Wang Q; Yu X; Yang N; Wang Y; Zeng Y; Zheng Z; Zhou F; Zhou Y
    Cell Death Dis; 2021 Apr; 12(4):370. PubMed ID: 33824311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
    Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
    Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
    Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
    Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
    Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
    Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.